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The multidisciplinary management of lung cancer has been univer-
sally accepted. In France, the multidisciplinary approach for cancer
patients is established by law. However, the efficacy of this ap-
proach remains theoretical, given that no evaluation criteria have
been made available and no previous reports have been published on
the prospective follow-up of these patients. The Groupe d’ Oncolo-
gie Thoracique Azure´en carried out a 1-year prospective study on
patients discussed during its multidisciplinary weekly meetings, to
analyze the concordance between the proposed and administered
treatment, the delay of treatment, and the 1-year actuarial survival.
Of the 344 patients discussed during the period considered, the
therapeutic decision was chemotherapy in 183 patients, surgery in
93, radiochemotherapy in 42, radiotherapy in 14, and supportive
care 12. Therapeutic discordance between the planned and the
administered treatment was recorded in 15 cases (4.4%), mainly for
patient’s refusal (seven cases) or poor performance status (five
cases). The median delay of treatment was 20 days, shorter for
chemotherapy (16 days), and longer for radiotherapy (27 days). The
overall 1-year survival rate was 51.4%: 80.4% for stage I, 50.3% for
stage II, 37.5% for stage III, and 27.2% for stage IV. For patients for
whom discordance of treatment was recorded, a lower survival rate
was recorded, without reaching statistical significance (0.07). In
conclusion, the efficacy of the Groupe d’ Oncologie Thoracique
Azure´en multidisciplinary management was confirmed, as we be-
lieve that a discordant rate of less than 5% and a delay of treatment
of 4 weeks can be considered acceptable. Furthermore, a periodic
survival evaluation of the population as a whole could provide
additional useful information for multidisciplinary groups.
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ment, Survival.
(J Thorac Oncol. 2007;2: 69–72)
The modern management of lung cancer should be multidis-ciplinary1,2 to facilitate precise staging and optimal treat-
ment. In France, this became law in 1998, stating that all
patients, no matter where they are treated, should benefit from a
diagnostic and therapeutic strategy defined by a multidisci-
plinary team composed of an oncologist, surgeon, organ special-
ist, pathologist, radiotherapist, and general practitioner.3
The therapeutic strategy decided by the multidisci-
plinary team must be derived from evidence-based guidelines
and ongoing clinical protocol tailored to patient information
given during the common clinical presentation of the case.
To verify the theoretical advantages of this approach,
follow-up information is needed to assess how many patients
did indeed receive the planned treatment and, in case of
discordance, to verify the cause. Unfortunately, there is
currently no information available in literature regarding the
follow-up of these patients after their multidisciplinary eval-
uation.
For these reasons, the Groupe d’Oncologie Thoracique
Azure´en (GOThA), the thoracic oncology group based in
Nice, started a 1-year prospective study to verify the fol-
low-up of patients after multidisciplinary discussion, with
particular attention given to the concordance between the
proposed and administered treatments.
PATIENTS AND METHODS
The main objective of this study was a prospective
assessment of the impact of the GOThA multidisciplinary
evaluation of lung cancer patients, verifying conformity be-
tween the planned and the administered treatments. Second-
ary objectives of the study were the assessment of the delay
of treatment (defined as the time [in days] from the first
multidisciplinary discussion to the date of initiating therapy)
and the analysis of the actuarial overall 1-year survival rate.
Multidisciplinary Evaluation
In France, all patients with a proven or possible diag-
nosis of lung cancer must be evaluated in a multidisciplinary
discussion during a “RCP” (Reunion de Concertation Pluri-
disciplinaire, meeting of multidisciplinary discussion). Nice
is the county seat of the French Alpes Maritimes Department
(4298 km2, 971,829 inhabitants), one of the six departments
of PACA region (Provence-Alpes-Coˆte d’Azur). At the time
of the study, there were three active thoracic oncology RCP
units in Alpes Maritimes Department, two of which were in
Nice. The general practitioner or specialist who needed to
evaluate a patient with lung cancer decided in which RCP to
present the case. Once the decision was made, it was his or
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her responsibility to follow the RCP recommendations or to
modify them based on the patient’s clinical course.
One of the Nice RCP weekly meetings is held by
GOThA. It is composed of 24 members representing seven
different specialties (thoracic surgery, thoracic oncology, pul-
monology, radiotherapy, radiology, pathology, and nuclear
medicine).
Study Population
The population was composed of all the patients with a
clinical diagnosis of lung cancer presented at the GOThA
weekly meeting for a 1-year period starting on July 1, 2003.
The reason for multidisciplinary evaluation was recorded for
each patient (diagnosis, first treatment, two or more treat-
ments, adjuvant treatment after surgery, follow-up). Lung
lesions were classified into four groups: histologically proven
lung cancer, high, intermediate, or low risk of lung cancer.
The therapeutic decision was classified in five different cat-
egories (surgery, chemotherapy, radiotherapy, chemoradio-
therapy, best supportive care). Patients receiving chemother-
apy and radiotherapy with palliative intent were assigned to
the chemotherapy group; those receiving only palliative ra-
diotherapy were assigned to the best supportive care group.
Patients entering multimodality protocols were discussed at
the GOThA meeting after each therapeutic step.
Staging Procedures
Staging procedures were performed according to FN-
CLCC (Fe´de´ration Nationale des Centres de Lutte contre le
Cancer) guidelines. In patients with clinical stage I–III suit-
able for curative treatment, bronchoscopy, computed tomog-
raphy scan of the chest and of the upper abdomen, and
positron emission tomography scan were routinely per-
formed. In cases of mediastinal lymph nodes larger than 1 cm
in their short axis, histologic confirmation was obtained by
mediastinoscopy, anterior mediastinotomy, or video-assisted
thoracoscopy, as needed. In patients with clinical stage IV
disease, only the presence of overwhelming clinical and
radiographic evidence of metastases was considered suffi-
cient for staging. In all the other suspected cases, tissue
confirmation of the metastatic site was considered mandatory
before chemotherapy. Candidate patients for palliative care
had chest and abdomen computed tomography evaluation
only.
Follow-up
After the multidisciplinary discussion, the physician
who first presented the case was contacted for the first time
after 2 months to verify the concordance and the delay of
treatment and thereafter every 2 months to check the patient’s
status and possibly the cause of death. A dedicated data
manager working 6 hours per week was needed during the
entire period of the study for data collection during the
weekly meetings and for patient follow-up.
The last data collection was performed in March 2005.
One-year survival curves were obtained using Kaplan-Meier
analysis for the whole population of patients with patholog-
ically proven lung cancer and were divided by stage.
RESULTS
Between July 1, 2003, and June 30, 2004, 344 patients
were presented at one of the 51 weekly GOThA meetings
with a clinical (97 patients) or pathologic (247 patients)
diagnosis of lung cancer. Characteristics of the population are
listed in Table 1. Therapeutic treatment was classified as
follows: surgical resection in 93 cases (27%), chemotherapy
in 183 cases (53.2%), chemoradiotherapy in 42 cases
(12.2%), radiotherapy in 14 cases (4.1%), and best supportive
care in 12 cases (3.5%) Table 2.
Treatment decision was made at the first multidisci-
plinary discussion for 164 patients (47.6%), at the second
presentation for 112 patients (32.6%), at the third presenta-
tion for 51 patients (14.8%), and later for 17 patients (5%).
At follow-up, discordance between the planned and
administered treatment was recorded in 15 patients (4.4%).
Seven patients (2%) refused the proposed treatment. In five
cases (1.4%), the clinical status of patients did not permit the
administration of treatment. In one case (0.3%), an 82-year-
old patient was proposed for supportive care. His physician
referred him to a different radiotherapist; he then underwent
radiotherapy and subsequently died of cardiac complications
due to preexisting aortic stenosis. In two cases (0.6%), the
referring physician was not able to contact the patients, and
they were considered as discordant cases.
It is of interest to note that the median age of discordant
cases was significantly higher than the median age of con-
cordant cases (74 versus 65 years, p  0.01). The rate of
discordance was higher for supportive care (2/12, 16.6%) and
radiotherapy (1/14, 7.1%) compared chemotherapy (5/183,
2.7%) and surgery (4/93, 4.3%).
The median overall delay from GOThA discussion to
treatment was 20 days. For chemotherapy, the median delay
TABLE 1. Clinical Characteristics of the Population: Clinical
Stage Defined for Each patient at the Time of the

















1 treatment 155 45.1
2 treatments 28 8.1
Adjuvant treatment 40 11.6
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was 16 days, 22 days for surgery, 24 days for chemoradio-
therapy, and 27 for radiotherapy.
At the last follow-up, 61 deaths were recorded, 57 of
them due to cancer-related causes. Mean follow-up time was
152.6  95.2 days. Overall 1-year actuarial survival rate for
the entire population was 51.4%: 80.4% for stage I, 50.3% for
stage II, 37.5% for stage III, and 27.2% for stage IV (2 
9.40, df  3, p  0.02). For patients who received RCP
treatment, a longer survival time was recorded as compared
to discordant cases, but the advantage was not statistically
significant (p  0.07).
DISCUSSION
Although multidisciplinary management of lung cancer
patients is widely recommended, very little information is
available on the actual impact of this approach. Moreover, the
complexity of multidisciplinary management makes it diffi-
cult to achieve satisfactory comprehensive evaluation. When
the study was started, three parameters were arbitrarily cho-
sen to test the efficacy of GOThA activity: the concordance
between the proposed and delivered treatment, the delay of
treatment, and the long-term survival. The concordance pa-
rameter was considered as the most important because mul-
tidisciplinary discussion affords the best treatment for each
patient based on clinical history, performance status, and
tumor stage. In our series, the rate of discordance was about
5%. Even in absence of data for comparison, we estimate this
discordance rate as acceptable, considering that discordance
was mainly due to patients’ refusal of treatment. Furthermore,
even if the population is too small for a multivariate analysis,
the two factors that seem to increase the risk of discordance
are the age of the patient and the choice of supportive care.
It is logical to assume that the more quickly treatment
is implemented, the more successful are the results. The
British Thoracic Society has stated that time span between the
first consultation with pulmonologist and the actual surgical
intervention should not exceed 8 weeks4, when feasible.
Keeping in mind these guidelines, the delay of treatment
reported in our study (1 month) can be considered acceptable,
considering that about 50% of patients needed more than one
presentation to receive a treatment decision and that the waste
of time due to potential multiple consultations with different
specialists was avoided. Even if a clear relationship between
an accelerated pathway to diagnosis or resection and a better
chance of survival is not supported by direct evidence,1 in our
opinion, the length of time between diagnosis and treatment
represents an important quality parameter.
Surprisingly, the 1-year survival was higher than ex-
pected.5 It is probably due to the rate of patients eligible for
curative treatment, as thoracic surgeon members of GOThA’s
RCP represent 90% of the thoracic surgical activity of the
region. Although the additional workload required for the col-
lection of survival information was substantial, the continuous
active follow-up maximally reduced the typical loss of informa-
tion, which becomes likely when data are collected 6 to 12
months after the event. Moreover, the multidisciplinary team
was able to monitor the prognosis of the population in real time.
The scientific impact of such information is limited; however, it
represents the results of treatments administered to an unselected
population, which provide a more realistic picture than those
obtained from patients selected for clinical trials.
Although not the primary objective of the study, the
trend toward increased survival in patients treated with the
multidisciplinary approach, as reported by other authors,6
seems to be confirmed and represents a stimulus toward
improving the efficacy of the multidisciplinary management
of lung cancer. From the practical point of view, the devel-
opment of a simple alphanumeric code to describe basic
patient information (such as age, diagnosis, stage, first treat-
ment, date and status of last follow-up) would help different
multidisciplinary groups in a data comparison. Moreover, the
use of telemedicine7 can probably reduce the waste of time due
to displacements and increase the frequency of multidisciplinary
meetings, which should ideally be held on a weekly basis.
In conclusion, given the fact that the multidisciplinary
approach in lung cancer is widely accepted but poorly eval-
uated, (1) quality parameters should be defined to increase
knowledge in this field, (2) the three parameters we tested
have proved to be satisfactory for this purpose, (3) further-
more, a discordant rate of less than 5% and a delay of
treatment of 4 weeks can be considered acceptable. Fi-
nally, a periodic survival evaluation from the overall popu-
lation represents an opportunity to collect additional useful
information.
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TABLE 2. Clinical Details from the 13 Patients for Whom a
Discordance of Treatment Was Recorded
Sex Age, y Decision Reason for discordance
F 72 Surgery Poor performance status
M 71 Supportive care Patient’s refusal
M 78 Chemotherapy Patient’s refusal
F 81 Radiotherapy Poor performance status
M 83 Surgery Poor performance status
M 78 Radiotherapy Poor performance status
M 82 Supportive care Contrary decision of the referring
physician
M 88 Surgery Poor performance status
M 73 Chemotherapy Patient’s refusal
M 75 Chemotherapy Patient’s refusal
F 78 Chemotherapy Patient’s refusal
M 50 Surgery Patient’s refusal
F 57 Chemotherapy Patient’s refusal
The referring physician was not able to further contact the patients in two cases and
they were considered as discordant.
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